natgillin/translations-raw huggingface dataset:
I forebyggelsesstudiet for kliniske frakturer efter en nylig hoftefraktur blev D-vitamin niveauet ikke målt rutinemæssigt, men flertallet af patienter modtog en støddosis D-vitamin forud for administrationen af zolidronsyre (se pkt.
In the trial for the prevention of clinical fractures following a recent hip fracture, vitamin D levels were not routinely measured but the majority of patients received a loading dose of vitamin D prior to zoledronic acid administration (see section 4.2).
øsofagit, tandpine, gastrit#
oesophagitis, toothache, gastritis#
Den anbefalede dosis er en enkelt intravenøs infusion af 5 mg Zoledronsyre Teva Pharma.
The recommended dose is a single intravenous infusion of 5 mg Zoledronic acid Teva Pharma.
Før du får Zoledronsyre Teva Pharma, skal du fortælle det til lægen, apoteket eller sundhedspersonalet: - hvis du er i behandling med anden medicin, der også indeholder zoledronsyre, der er det samme aktive stof i Zoledronsyre Teva Pharma (zoledronsyre bruges til voksne patienter med visse kræftformer for at forebygge knoglekomplikationer eller for at nedsætte mængden af calcium).
Talk to your doctor, pharmacist or nurse before you are given Zoledronic acid Teva Pharma: - if you are being treated with any medicine containing zoledronic acid, which is also the active substance of Zoledronic acid Teva Pharma (zoledronic acid is used in adult patients with certain types of cancer to prevent bone complications or to reduce the amount of calcium).
Lægen, apoteket eller sygeplejersken ved, hvordan Zoledronsyre Teva Pharma skal opbevares korrekt.
Your doctor, pharmacist or nurse knows how to store Zoledronic acid Teva Pharma properly.
Patienter skal være passende hydreret før administration af Zoledronsyre Teva Pharma.
Patients must be appropriately hydrated prior to administration of Zoledronic acid Teva Pharma.
Hændelsesraten for hoftefrakturer var 1,44 % for patienter behandlet med zoledronsyre sammenlignet med 2,49 % for patienter behandlet med placebo.
The hip fracture event rate was 1.44% for zoledronic acidtreated patients compared to 2.49% for placebo-treated patients.
Den sædvanlige dosis er 5 mg, der gives som én infusion pr. år i en vene af din læge eller sundhedspersonalet.
The usual dose is 5 mg given as one infusion per year into a vein by your doctor or nurse.
Hvis du for nylig har brækket din hofte, anbefales det at zoledronsyre gives i to eller flere uger efter din hofteoperation.
In case you recently broke your hip, it is recommended that Zoledronic acid Teva Pharma is administered two or more weeks after your hip repair surgery.
• Kontraindikationer hos gravide og ammende kvinder
• Contraindication in pregnancy and in breast-feeding women
Ikke almindelig Nedsat appetit
Hypocalcaemia* Uncommon Decreased appetite
Din læge vil vejlede dig og beslutte, hvor længe du skal behandles med Zoledronsyre Teva Pharma.
Your doctor will advise you and decide how long you should be treated with Zoledronic acid Teva Pharma.
Hos patienter med Pagets sygdom er symptomer på grund af lavt calciumindhold i blodet, fx muskelkramper, følelsesløshed eller en snurrende fornemmelse især omkring munden blevet rapporteret.
In patients with Paget's disease: symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported.
• hos voksne mænd med øget risiko for fraktur, inklusive personer med en nylig lavenergi-hoftefraktur.
• in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture.
Zoledronsyre Teva Pharma bruges også til patienter, der for nylig har brækket deres hofte ved et mindre uheld, fx ved fald, og som derfor har risiko for yderligere knoglebrud.
Zoledronic acid Teva Pharma is also used in patients who have recently broken their hip in a minor trauma such as a fall and therefore are at risk of subsequent bone breaks.
Din læge kan råde dig til at tage et tilskud af calcium og D-vitamin (fx tabletter) i mindst de første ti dage, efter du har fået Zoledronsyre Teva Pharma.
Your doctor may advise you to take calcium and vitamin D supplements (e.g. tablets) for at least the first ten days after being given Zoledronic acid Teva Pharma.
Den leveres i en foliepose af polyolefin/styrenethylen-butylen (SEB) i en folieyderpose.
It comes in a polyolefin/styreneethylene-butylene (SEB) foil bag with a foil over pouch.
• Nødvendigheden af at infusere Zoledronsyre Teva Pharma langsomt over en periode på mindst
• Need to infuse Zoledronic acid Teva Pharma slowly over a period of no less than 15 minutes
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med referenceproduktet indeholdende zoledronsyre i alle undergrupper af den pædiatriske population for Pagets knoglesygdom, osteoporose hos mænd og post-menopausale kvinder med øget risiko for fraktur, og forebyggelse af kliniske frakturer efter hoftefraktur hos mænd og kvinder (se pkt.
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing zoledronic acid in all subsets of the paediatric population in Paget's disease of the bone, osteoporosis in post-menopausal women at an increased risk of fracture, osteoporosis in men at increased risk of fracture and prevention of clinical fractures after a hip fracture in men and women (see section 4.2 for information on paediatric use).
Zoledronsyre Teva Pharma leveres i multipakninger bestående af 5 (5 x 1) eller 10 (10 x 1) poser.
Zoledronic acid Teva Pharma is supplied in multipacks of 5 (5 x 1) or 10 (10 x 1) bags .
Det vil hjælpe dig med at undgå væsketab.
This will help prevent dehydration.
Følg nøje alle lægens, farmaceutens eller sundhedspersonalets instruktioner, før du anvender Zoledronsyre Teva Pharma.
Follow all instructions given to you by your doctor, pharmacist or nurse carefully before you are given Zoledronic acid Teva Pharma.
Eksisterende hypokalcæmi skal behandles med tilstrækkelig indgivelse af calcium og D-vitamin, før behandling med Zoledronsyre Teva Pharma initieres (se pkt.
Pre-existing hypocalcaemia must be treated by adequate intake of calcium and vitamin D before initiating therapy with Zoledronic acid Teva Pharma (see section 4.3).
Før du får Zoledron Teva Pharma-behandling, skal du fortælle din læge, farmaceut eller sundhedspersonale, hvis - du har nogle problemer med din mund eller tænder, som fx dårlig mundhygiejne,
Before receiving Zoledronic acid Teva Pharma treatment, tell your doctor, pharmacist or nurse if - you have any problems with your mouth or teeth such as poor dental health, gum disease, or a
Forsigtighed tilrådes når Zoledronsyre Teva Pharma administreres samtidig med lægemidler, der har en signifikant indvirkning på nyrefunktionen (fx aminoglykosider eller diuretika, som kan forårsage dehydrering) (se pkt.
Caution is indicated when Zoledronic acid Teva Pharma is administered in conjunction with medicinal products that can significantly impact renal function (e.g. aminoglycosides or diuretics that may cause dehydration) (see section 4.4).
Frekvensen af atrieflimren som alvorlig utilsigtigt hændelse var øget hos patienter i behandling med zoledronsyre (1,3 %) (51 ud af 3.862) sammenlignet med patienter som modtog placebo (0,6 %) (22 ud af 3.852).
The rate of atrial fibrillation serious adverse events was increased in patients receiving zoledronic acid (1.3%) (51 out of 3,862) compared with patients receiving placebo (0.6%) (22 out of 3,852).
Kontraindikationer hos patienter med kreatininclearance <35 ml/min
• Contraindication in patients with creatinine clearance < 35 ml/min
Zoledronsyre Teva Pharma leveres i pakninger bestående af 1 flaske og multipakninger bestående af 5 (5 x 1) eller 10 (10 x 1) flasker.
Zoledronic acid Teva Pharma is supplied in packs of 1 bottle and multipacks of 5 (5 x 1) or 10 (10 x 1) bottles.
Flerlagspose af polyolefin/styren-ethylen-butylen (SEB) med SFC polypropyleninfusionsport lukket med gummiprop og låg.
Multilayer polyolefin/styrene-ethylene-butylene (SEB) bag with SFC polypropylene infusion port closed with rubber stopper and snap cap.
Nedsat nyrefunktion er set efter administration af zoledronsyre, specielt hos patienter med eksisterende nyreproblemer eller yderligere risikofaktorer (fx ældre patienter, cancerpatienter i kemoterapibehandling, samtidig behandling med nefrotoksiske lægemidler, samtidig behandling med diuretika, svær dehydrering), hvoraf de fleste modtog en dosis på 4 mg hver 3-4. uge, men det er set hos patienter efter en enkelt administration.
Renal impairment has been observed following the administration of zoledronic acid, especially in patients with pre-existing renal dysfunction or additional risk factors (e.g. advanced age, oncology patients with chemotherapy, concomitant nephrotoxic medicinal products, concomitant diuretic therapy, severe dehydration), with the majority of them receiving a 4 mg dose every 3-4 weeks, but it has been observed in patients after a single administration.
Zoledronsyre Teva Pharma er kontraindiceret under graviditet (se pkt.
Zoledronic acid Teva Pharma is contraindicated during pregnancy (see section 4.3).
Efter åbning: 24 timer ved 2°C-8°C.
After opening: 24 hours at 2°C - 8°C
Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel.
You can also report side effects directly the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Hjælpestoffer: Mannitol, natriumcitrat og vand til injektionsvæsker.
Excipients: Mannitol, sodium citrate and water for injections.
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. 100 ml, dvs. det er i det væsentlige natriumfrit.
This medicinal product contains less than 1 mmol sodium (23 mg) per 100 ml, i.e. essentially “sodium-free.”
Zoledronsyre Teva Pharma administreres via en separat infusionsslange og ved en langsom konstant infusionshastighed.
Zoledronic acid Teva Pharma is administered via a vented infusion line and given slowly at a constant infusion rate.
Zoledronsyre Teva Pharma må ikke komme i kontakt med calciumholdige opløsninger.
Zoledronic acid Teva Pharma must not be allowed to come into contact with any calcium-containing solutions.
Din læge vil måske bede dig om at få et tandeftersyn, før du starter behandling med Zoledronsyre Teva Pharma.
Your doctor may ask you to undergo a dental examination before you start treatment with Zoledronic acid Teva Pharma.
Det er vigtigt, at du drikker mindst 2 glas væske (fx vand), inden for et par timer før behandling med Zoledronsyre Teva Pharma, som anvist af sundhedspersonalet.
It is important for you to drink at least 2 glasses of fluid (such as water), within a few hours before receiving Zoledronic acid Teva Pharma, as directed by your healthcare provider.
Zoledronsy re (N=3.875) hændelsesrate (%)
Zoledronic acid (N=3,875) event rate
Klinisk effekt ved osteoporose i forbindelse med længerevarende systemisk glukokortikoidbehandling Effekten og sikkerheden af zoledronsyre ved behandling og forebyggelse af osteoporose i forbindelse med længerevarende systemisk glukokortikoidbehandling blev vurderet i et randomiseret, multicenter, dobbeltblindet, stratificeret, aktivt kontrolleret studie med 833 mænd og kvinder i alderen 18-85 år (gennemsnitsalder for mænd 56,4 år; for kvinder 53,5 år) behandlet med > 7,5 mg prednisolon (eller tilsvarende) oralt dagligt.
Clinical efficacy in osteoporosis associated with long-term systemic glucocorticoid therapy The efficacy and safety of zoledronic acid in the treatment and prevention of osteoporosis associated with long-term systemic glucocorticoid therapy were assessed in a randomised, multicentre, doubleblind, stratified, active-controlled study of 833 men and women aged 18-85 years (mean age for men 56.4 years; for women 53.5 years) treated with > 7.5 mg/day oral prednisone (or equivalent).
Tabel 4 Sammenligninger mellem behandlinger af incidensen af vigtige kliniske
Table 4 Between treatment comparisons of the incidence of key clinical fracture variables Outcome
Risikoen for at få disse bivirkninger aftager ved de efterfølgende doser Zoledronsyre Teva Pharma.
The chance of experiencing these side effects decreases with subsequent doses of Zoledronic acid Teva Pharma.
Ikke kendt (hyppigheden kan ikke vurderes ud fra tilgængelige data) Smerter i mund og/eller kæbe, hævelse eller manglende sårheling i munden eller kæben, pus fra såretfølelsesløshed eller en følelse af tunghed i kæben, eller løsnen af en tand; dette kan være tegn på knogleskade i kæben (osteonekrose).
Not known (frequency cannot be estimated from the available data) Pain in the mouth, and/or jaw, swelling or non-healing sores in the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth; these could be signs of bone damage in the jaw (osteonecrosis).
Før markedsføring i medlemsstaterne skal indehaveren af markedsføringstilladelsen (MAH) skal sørge for et uddannelsesprogram, der er udarbejdet til alle læger, der forventes at udskrive/anvende Zoledronsyre Teva Pharma til behandling af osteoporose.
The Marketing Authorisation Holder (MAH) shall provide an educational programme targeting all physicians who are expected to prescribe/use Zoledronic acid Teva Pharma for the treatment of osteoporosis prior to the launch in Member States.
Zoledronsyre Teva Pharma indeholder natrium Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. 100 ml, det vil sige er praktisk taget "natriumfrit".
Zoledronic acid Teva Pharma contains sodium This medicine contains less than 1 mmol sodium (23 mg) per 100 ml, i.e. essentially “sodium-free.”
Den renale clearance af zoledronsyre korrelerer tydeligt med kreatininclearance, idet den renale clearance udgjorde 7533 % af kreatininclearance, hvilket viste en median på 8429 ml/min
The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 ± 33% of the creatinine clearance, which showed a mean of 84 ± 29 ml/min (range 22 to 143 ml/min) in the 64 patients studied.
Din læge bør tage en blodprøve for at kontrollere din nyrefunktion (kreatininniveau) før hver Zoledronsyre Teva Pharma-dosis.
Your doctor should do a blood test to check your kidney function (levels of creatinine) before each dose of Zoledronic acid Teva Pharma.
Hos patienter med en nylig lavenergi-hoftefraktur anbefales det at administrere Zoledronsyre Teva Pharma-infusion mindst to uger efter hoftefrakturhelingen (se pkt.
In patients with a recent low-trauma hip fracture, it is recommended to give the zoledronic acid infusion at least two weeks after hip fracture repair (see section 5.1).
Din læge bør tage en blodprøve for at kontrollere din nyrefunktion før hver Zoledronsyre Teva Pharma-dosis.
Your doctor should do a blood test to check your kidney function before each dose of Zoledronic acid Teva Pharma.
Zoledronsyre Teva Pharma indeholder det aktive stof zoledronsyre.
Zoledronic acid Teva Pharma contains the active substance zoledronic acid.
Patienter i behandling med Zoledronsyre Teva Pharma bør få udleveret indlægssedlen og patienthuskekortet.
Patients treated with Zoledronic acid Teva Pharma should be given the package leaflet and the patient reminder card.
Du eller dine pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V*.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Mindst en ny vertebral fraktur (0-1 år) Mindst en ny vertebral fraktur (0-2 år) Mindst en ny vertebral fraktur (0-3 år) ** p <0,0001
At least one new vertebral fracture (0-3 year)
Zoledronsyre Teva Pharma er kontraindiceret til patienter med kreatininclearance < 35 ml/min (se pkt.
Zoledronic acid Teva Pharma is contraindicated in patients with creatinine clearance < 35 ml/min (see sections 4.3 and 4.4).
Udløbsdato Efter åbning: 24 timer ved 2°C-8°C.
EXP After opening: 24 hours at 2°C - 8°C
Det anbefales at indtage tilstrækkeligt med calcium og D-vitamin i forbindelse med administration af Zoledronsyre Teva Pharma.
Adequate calcium and vitamin D intake are recommended in association with Zoledronic acid Teva Pharma administration.
Yderligere tilrådes det kraftigt hos patienter med Pagets sygdom, at sikre et tilstrækkeligt calciumtilskud svarende til mindst 500 mg calcium to gange daglig i mindst 10 dage efter administration af Zoledronsyre Teva Pharma (se pkt.
In addition, in patients with Paget's disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zoledronic acid Teva Pharma administration (see section 4.2).
5.1) var den generelle forekomst af atrieflimren 2,5 % (96 ud af 3.862) og 1,9 % (75 ud af 3.852) hos patienter, som fik henholdsvis zoledronsyre og placebo.
In the HORIZON - Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid and placebo, respectively.
Zoledronsyre Teva Pharma indeholder: - Aktivt stof: zoledronsyre.
What Zoledronic acid Teva Pharma contains - The active substance is zoledronic acid.
Det tilrådes kraftigt hos patienter med Pagets sygdom at sikre et tilstrækkeligt calciumtilskud svarende til mindst 500 mg calcium to gange daglig, i mindst 10 dage efter administration af Zoledronsyre Teva Pharma (se pkt.
In patients with Paget's disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zoledronic acid Teva Pharma administration (see section 4.4).
Patientinformationsmaterialet skal indeholde følgende hovedelementer:
The patient educational material should contain the following key messages:
Du må ikke få Zoledronsyre Teva Pharma - hvis du er allergisk over for zoledronsyre, andre bisfosfonater eller et af de øvrige indholdsstoffer i Zoledronsyre Teva Pharma (angivet i punkt 6).
- if you are allergic to zoledronic acid, other bisphosphonates or any of the other ingredients of this medicine (listed in section 6).
- Zoledronsyre Teva Pharma 5 mg infusionsvæske, opløsning er klar til brug.
- Zoledronic acid Teva Pharma 5 mg solution for infusion is ready for use.
Lægeundervisningsmateriale skal indeholde følgende hovedelementer:
The physician educational material should contain the following key messages:
• Doseringsregime én gang årligt.
• Once-yearly dosing regime
• Nødvendigheden af inden hver behandling med Zoledronsyre Teva Pharma at beregne kreatininclearance på basis af den faktiske legemsvægt ved at bruge Cockcroft-Gault formlen
• Need to calculate creatinine clearance based on actual body weight using the Cockcroft-Gault formula before each treatment with Zoledronic acid Teva Pharma
Sørg for at drikke tilstrækkelig væske (mindst 1 eller 2 glas) før og efter behandling med Zoledronsyre Teva Pharma, som din læge har fortalt dig.
Zoledronic acid Teva Pharma with food and drink Make sure you drink enough fluids (at least one or two glasses) before and after the treatment with Zoledronic acid Teva Pharma, as directed by your doctor.
For information angående infusion af Zoledronsyre Teva Pharma se pkt.
For information on the infusion of Zoledronic acid Teva Pharma, see section 6.6.
Efter åbning: Kemisk og fysisk stabilitet er påvist i 24 timer ved 2-8°C og 25°C.
After opening: Chemical and physical in-use stability has been demonstrated for 24 hours at 2 to 8°C and 25ºC.
Teva Pharmaceuticals Ireland Tel: +353 51 321 740
Teva Pharmaceuticals Ireland, L-Irlanda Tel: +353 51 321740
Sjældne tilfælde af dialysekrævende nyresvigt og sjældne tilfælde med letal udgang er rapporteret hos patienter med forudeksisterende nedsat nyrefunktion eller andre risikofaktorer som fremskreden alder, samtidig anvendelse af nefrotoksiske lægemidler, samtidig anvendelse af diuretika eller dehydrering efter behandlingen med Zoledronsyre Teva Pharma (se pkt.
Rare cases of renal failure requiring dialysis and rare cases with a fatal outcome have been reported in patients with pre-existing renal dysfunction or other risk factors such as advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy, or dehydration in the post infusion period (see sections 4.4 and 4.8
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/12/772/003 multipakning med 5 poser
MARKETING AUTHORISATION NUMBER(S) EU/1/12/772/003 multipack with 5 bags
- Overfølsomhed over for det aktive stof, over for andre bisfosfonater eller over for et eller flere af hjælpestofferne, anført i pkt.
- Hypersensitivity to the active substance, to any bisphosphonates or to any of the excipients, listed in section 6.1.
- Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og posen efter EXP. - Må ikke opbevares ved temperaturer under 30°C.
- Do not use this medicine after the expiry date which is stated on the carton and bag after EXP. - Store below 30°C.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver flaske med 100 ml opløsning indeholder 5 mg zoledronsyre (som monohydrat).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each bottle with 100 ml of solution contains 5 mg zoledronic acid (as monohydrate).
Kvinder i den fertile alder Zoledronsyre Teva Pharma bør ikke anvendes til kvinder i den fertile alder.
Women of childbearing potential Zoledronic acid Teva Pharma is not recommended in women of childbearing potential.
Hvis præparatet ikke bruges med det samme, er brugeren ansvarlig for opbevaringstid og -betingelser, som normalt ikke vil være længere end 24 timer ved 2°C - 8°C.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C - 8°C.
I undergruppen med patienter, der havde fået glukokortikoider i 3 måneder eller derunder før randomisering, øgede zoledronsyre lænderygsøjlens BMD med 4,06 % i forhold til 2,71 % for risedronat (middeldifference: 1,36 %; p < 0,001).
In the subpopulation of patients receiving glucocorticoids for more than 3 months prior to randomisation, zoledronic acid increased lumbar spine BMD by 4.06% versus 2.71% for risedronate (mean difference: 1.36%; p<0.001).
Meget almindelige (kan forekomme hos flere end 1 ud af 10 patienter) Feber.
Very rare (may affect up to 1 in 10,000 people)
EU/1/12/772/004 multipakning med 10 poser
EU/1/12/772/004 multipack with 10 bags
I undergruppen med patienter, der havde fået glukokortikoider i mindre end 3 måneder før randomisering, øgede zoledronsyre BMD i lænderygsøjlen med 2,60 % i forhold til 0,64 % for risedronat (middeldifference: 1,96 %; p > 0,001).
In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, zoledronic acid increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96% ; p<0.001).
Multipakning: 5 poser med 100 ml
Solution for infusion Multipack: 5 bags of 100 ml Multipack: 10 bags of 100 ml
Den sædvanlige dosis er 5 mg, som indgives af din læge eller sundhedspersonalet som en infusion i en vene.
The usual dose is 5 mg, given to you as one initial infusion into a vein by your doctor or nurse.
Multipakning: 5 flasker med 100 ml
Solution for infusion Multipack: 5 bottles of 100 ml Multipack: 10 bottles of 100 ml
Det anbefales at give en støddosis D-vitamin på 50.000 til 125.000 IE oralt eller intramuskulært før den første Zoledronsyre Teva Pharma-infusion hos patienter med en nylig lavenergi-hoftefraktur.
In patients with a recent lowtrauma hip fracture, a loading dose of 50 000 to 125 000 IU of vitamin D given orally or via the intramuscular route is recommended prior to the first zoledronic acid infusion.
Tilfælde af osteonekrose af kæberne er blevet rapporteret efter markedsføring for Zoledronsyre Teva Pharma.
Cases of ONJ have been reported in the postmarketing setting for Zoledronic acid Teva Pharma.
Tilberedelse og administration af Zoledronsyre Teva Pharma:
How to prepare and administer Zoledronic acid Teva Pharma